Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib.

Sara Völkel, Thomas S Tarawneh,Laura Sacher,Aditya M Bhagwat, Ihab Karim,Hildegard I D Mack,Thomas Wiesmann, Björn Beutel,Joachim Hoyer,Christian Keller,Harald Renz,Andreas Burchert,Andreas Neubauer,Johannes Graumann,Chrysanthi Skevaki,Elisabeth K M Mack

Frontiers in medicine（2023）

引用 0|浏览13

暂无评分

摘要

Our results indicate that the mechanism of action of Ruxo in COVID-19-ARDS can be related to both known effects of this drug as a modulator of T-cells and the SARS-CoV-2-infection.

查看译文

关键词

acute respiratory distress syndrome, COVID-19, proteomics, Ruxolitinib, SARS-CoV-2

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要